Zolav®: a new antibiotic for the treatment of acne

Medicine and Dentistry

• Acneiform Eruption 100%
• Propionibacterium acnes 100%
• Antimicrobial Agent 100%
• Colony Forming Unit 66%
• Growth Inhibition 66%
• Cytotoxicity 66%
• Colony Forming Unit S 66%
• Acne Vulgaris 66%
• Lung 33%
• Infection 33%
• Escherichia coli 33%
• Mutagenicity 33%
• Bacterial Growth 33%
• Tryptophan 33%
• Serial Dilution 33%
• Treatment Group 33%
• Human Umbilical Vein Endothelial Cell 33%
• Auxotrophic Mutant 33%
• Isotretinoin 33%
• Retinol Derivative 33%
• Treatment Option 33%

Immunology and Microbiology

• Antimicrobial Agent 100%
• Propionibacterium acnes 100%
• Minimum Inhibitory Concentration 66%
• Cytotoxicity 66%
• Colony Forming Unit S 66%
• Infectious Disease 33%
• Umbilical Vein Endothelial Cell 33%
• Escherichia coli 33%
• Dilution 33%
• Mutagenicity 33%
• Tryptophan 33%
• Bacterial Growth 33%
• Growth Inhibition 33%
• Isotretinoin 33%
• Growth Inhibitory Concentration 33%
• Auxotrophic Mutant 33%
• Infection 33%
• Susceptibility 33%
• Lung 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Acne 100%
• Propionibacterium acnes 100%
• Antimicrobial Agent 100%
• Minimum Inhibitory Concentration 66%
• Cytotoxicity 66%
• Acne Vulgaris 66%
• Mutagenicity 33%
• Retinol Derivative 33%
• Infection 33%
• Escherichia coli 33%
• Treatment Group 33%
• Tryptophan 33%
• Isotretinoin 33%